Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.11 -1.36%

-$0.06 today

Market cap
$217.99M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.57M

Average 0.49M

BCYC Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Bicycle Therapeutics plcNASDAQ: BCYC

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 69.68M shares rose 0.7% year over year, behind the +7.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +32.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.7% toward the trailing-twelve-month pace of +7.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
69.68M+0.5% QoQ
Last fiscal yearDec 2025
69.28M+19.0% YoY
LTMMar 2026
69.4M+7.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.7%——
1 year+19.0%——
3-year CAGR+32.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
69.28M USD
Year-over-year change
+19.0%
4-year CAGR
+28.9%

Weighted Avg Shares vs competitors

How BCYC compares with its peers on the latest reported figures

  • BCYC's LTM Mar 2026 weighted avg shares of 69.4M shares is the 5th highest of the 10 companies compared; the peer median is 66.18M shares.
  • Its year-over-year change of +7.1% is the 6th highest of 9, against a peer median of +8.9%.
  • Over three fiscal years its annual growth of +32.7% compares with a peer median of +13.3%.
BCYC Competitors Peer median
Weighted Avg Shares for BCYC and competitors
Company Period LTM YoY 3-year CAGR
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026372.59M +6.8%+29.9%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
CMPXCompass Therapeutics, Inc.LTM Mar 2026161.95M +17.8%+14.5%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
BCYCBicycle Therapeutics plcLTM Mar 202669.4M +7.1%+32.7%
FULCFulcrum Therapeutics, Inc.LTM Mar 202666.18M +9.8%+12.1%
OMEROmeros CorporationLTM Mar 202665.07M +12.1%+0.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
PRTAProthena Corporation plcLTM Mar 202653.8M -0.0%+4.4%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202552.2M ——
Peer median (excluding BCYC) 66.18M+8.9%+13.3%

Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.7M14.46M26.98M35.28M72.59M
Cost of Revenue00156.5M172.97M0
Gross Profit11.7M14.46M(129.52M)(137.69M)72.59M
Gross Margin100.0%100.0%-480.1%-390.3%100.0%
Research & Development44.88M81.61M156.5M172.97M240.28M
Selling, General & Admin32.44M49.51M59.83M71.46M80.02M
Operating Expenses77.32M131.12M60.43M72.18M320.3M
Depreciation & Amortization1.41M3.69M6.55M7.18M6.42M
EBITDA(64.09M)(107.21M)(169.4M)(164.89M)(212.18M)
EBITDA Margin-547.9%-741.3%-628.0%-467.4%-292.3%
Operating Income(65.62M)(116.65M)(189.95M)(209.87M)(247.72M)
Operating Margin-561.0%-806.6%-704.1%-595.0%-341.3%
Interest Income120K5.76M14M34.28M28.46M
Interest Expense2.98M3.34M3.26M1.73M206K
Other Income / Expenses(2.86M)2.41M10.74M36.08M28.91M
Income Before Tax(68.48M)(114.24M)(179.21M)(173.8M)(218.81M)
Pre-Tax Margin-585.5%-789.9%-664.3%-492.7%-301.4%
Income Tax Expense(1.66M)(1.52M)1.46M(4.77M)152K
Net Income(66.82M)(112.72M)(180.66M)(169.03M)(218.96M)
Net Margin-571.2%-779.3%-669.7%-479.2%-301.7%
EPS (Basic)(2.67)(3.80)(5.08)(2.91)(3.16)
EPS (Diluted)(2.67)(3.80)(5.08)(2.90)(3.16)
Weighted Avg Shares25.06M29.66M35.59M58.21M69.28M
Weighted Avg Shares (Diluted)25.06M29.66M35.59M58.21M69.28M

Bicycle Therapeutics plc

NASDAQ:BCYC

Intrinsic Alpha fair value

Locked

Current Price

$3.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.